These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 22606221)

  • 1. Structural insights into human peroxisome proliferator activated receptor delta (PPAR-delta) selective ligand binding.
    Batista FA; Trivella DB; Bernardes A; Gratieri J; Oliveira PS; Figueira AC; Webb P; Polikarpov I
    PLoS One; 2012; 7(5):e33643. PubMed ID: 22606221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The peroxisome proliferator-activated receptor N-terminal domain controls isotype-selective gene expression and adipogenesis.
    Hummasti S; Tontonoz P
    Mol Endocrinol; 2006 Jun; 20(6):1261-75. PubMed ID: 16556736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peroxisome proliferator-activated receptors (PPARs) have multiple binding points that accommodate ligands in various conformations: phenylpropanoic acid-type PPAR ligands bind to PPAR in different conformations, depending on the subtype.
    Kuwabara N; Oyama T; Tomioka D; Ohashi M; Yanagisawa J; Shimizu T; Miyachi H
    J Med Chem; 2012 Jan; 55(2):893-902. PubMed ID: 22185225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural Basis for Anti-non-alcoholic Fatty Liver Disease and Diabetic Dyslipidemia Drug Saroglitazar as a PPAR α/γ Dual Agonist.
    Honda A; Kamata S; Satta C; Machida Y; Uchii K; Terasawa K; Nemoto A; Oyama T; Ishii I
    Biol Pharm Bull; 2021; 44(9):1210-1219. PubMed ID: 34471049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional and Structural Insights into Human PPARα/δ/γ Subtype Selectivity of Bezafibrate, Fenofibric Acid, and Pemafibrate.
    Honda A; Kamata S; Akahane M; Machida Y; Uchii K; Shiiyama Y; Habu Y; Miyawaki S; Kaneko C; Oyama T; Ishii I
    Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Crystal structures of the ligand-binding domain of human peroxisome proliferator-activated receptor δ in complexes with phenylpropanoic acid derivatives and a pyridine carboxylic acid derivative.
    Oyama T; Takiguchi K; Miyachi H
    Acta Crystallogr F Struct Biol Commun; 2022 Feb; 78(Pt 2):81-87. PubMed ID: 35102897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Are fish oil omega-3 long-chain fatty acids and their derivatives peroxisome proliferator-activated receptor agonists?
    Gani OA
    Cardiovasc Diabetol; 2008 Mar; 7():6. PubMed ID: 18355413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-based virtual screening and discovery of New PPARδ/γ dual agonist and PPARδ and γ agonists.
    Maltarollo VG; Togashi M; Nascimento AS; Honorio KM
    PLoS One; 2015; 10(3):e0118790. PubMed ID: 25767888
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A pan-PPAR ligand induces hepatic fatty acid oxidation in PPARalpha-/- mice possibly through PGC-1 mediated PPARdelta coactivation.
    Røst TH; Haugan Moi LL; Berge K; Staels B; Mellgren G; Berge RK
    Biochim Biophys Acta; 2009 Nov; 1791(11):1076-83. PubMed ID: 19577662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peroxisome proliferator-activated receptor agonists and antagonists: a patent review (2014-present).
    Takada I; Makishima M
    Expert Opin Ther Pat; 2020 Jan; 30(1):1-13. PubMed ID: 31825687
    [No Abstract]   [Full Text] [Related]  

  • 11. Switching subtype-selectivity: Fragment replacement strategy affords novel class of peroxisome proliferator-activated receptor α/δ (PPARα/δ) dual agonists.
    Shioi R; Okazaki S; Noguchi-Yachide T; Ishikawa M; Makishima M; Hashimoto Y; Yamaguchi T
    Bioorg Med Chem Lett; 2017 Jul; 27(14):3131-3134. PubMed ID: 28539218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrated virtual screening for the identification of novel and selective peroxisome proliferator-activated receptor (PPAR) scaffolds.
    Nevin DK; Peters MB; Carta G; Fayne D; Lloyd DG
    J Med Chem; 2012 Jun; 55(11):4978-89. PubMed ID: 22582973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular determinants for nuclear receptors selectivity: chemometric analysis, dockings and site-directed mutagenesis of dual peroxisome proliferator-activated receptors α/γ agonists.
    Carrieri A; Giudici M; Parente M; De Rosas M; Piemontese L; Fracchiolla G; Laghezza A; Tortorella P; Carbonara G; Lavecchia A; Gilardi F; Crestani M; Loiodice F
    Eur J Med Chem; 2013 May; 63():321-32. PubMed ID: 23502212
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural determinants of the agonist-independent association of human peroxisome proliferator-activated receptors with coactivators.
    Molnár F; Matilainen M; Carlberg C
    J Biol Chem; 2005 Jul; 280(28):26543-56. PubMed ID: 15888456
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ligand- and structure-based drug design strategies and PPARδ/α selectivity.
    Maltarollo VG; Honório KM
    Chem Biol Drug Des; 2012 Oct; 80(4):533-44. PubMed ID: 22672760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monitoring Solution Structures of Peroxisome Proliferator-Activated Receptor β/δ upon Ligand Binding.
    Schwarz R; Tänzler D; Ihling CH; Sinz A
    PLoS One; 2016; 11(3):e0151412. PubMed ID: 26992147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Scintillation Proximity Assay (SPA)-Based Radioligand Binding for PPARα, PPARγ, and PPARδ Receptors.
    Grether U; Benz J; Hartung T; Roth D
    Methods Mol Biol; 2023; 2576():145-153. PubMed ID: 36152183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. X-ray crystal structure of rivoglitazone bound to PPARγ and PPAR subtype selectivity of TZDs.
    Rajapaksha H; Bhatia H; Wegener K; Petrovsky N; Bruning JB
    Biochim Biophys Acta Gen Subj; 2017 Aug; 1861(8):1981-1991. PubMed ID: 28499821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sulfonylthiadiazoles with an unusual binding mode as partial dual peroxisome proliferator-activated receptor (PPAR) γ/δ agonists with high potency and in vivo efficacy.
    Keil S; Matter H; Schönafinger K; Glien M; Mathieu M; Marquette JP; Michot N; Haag-Diergarten S; Urmann M; Wendler W
    ChemMedChem; 2011 Apr; 6(4):633-53. PubMed ID: 21400663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural basis for iloprost as a dual peroxisome proliferator-activated receptor alpha/delta agonist.
    Jin L; Lin S; Rong H; Zheng S; Jin S; Wang R; Li Y
    J Biol Chem; 2011 Sep; 286(36):31473-9. PubMed ID: 21775429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.